Detection of breast cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry tissue and serum protein profiling

International Journal of Biological Markers

Volumn 24, Issue 3, 2009, Pages 130-141

  Gast, Marie Christine W ^a   van Dulken, Eric J ^b   van Loenen, Thea K G ^b   Kingma Vegter, Florine ^b   Westerga, Johan ^b   Flohil, Claudie C ^b   Knol, Jaco C ^c   Jimenez, Connie R ^c   van Gils, Carla H ^d   Wessels, Lodewijk F A ^a,e   Schellens, Jan H M ^f,g   Beijnen, Jos H ^a,g  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

^f ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^g UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Breast cancer; SELDI TOF MS; Serum; Tissue

Indexed keywords

ALBUMIN;

ADULT; AMINO TERMINAL SEQUENCE; ARTICLE; BENIGN TUMOR; BREAST CANCER; CANCER CLASSIFICATION; CANCER STAGING; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; SERUM; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; VALIDATION PROCESS;

EID: 70449378701     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2009.3475     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Ries LA, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975-2004. National Cancer Institute, US National Institutes of Health. 2008. Available at: http://seer.cancer.gov/csr/1975_2004/. Accessed July 24, 2009.
3. Stieber P, Molina R, Chan DW, et al. Clinical evaluation of the Elecsys CA 15-3 test in breast cancer patients. Clin Lab 2003; 49: 15-24.
4. Engwegen JY, Gast MC, Schellens JH, Beijnen JH. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci 2006; 27: 251-9.
5. Banks RE, Dunn MJ, Hochstrasser DF, et al. Proteomics: new perspectives, new biomedical opportunities. Lancet 2000; 356: 1749-56.
6. Hutchens TW, Yip TT. New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun Mass Spectrom 1993; 7: 576-80.
7. Belluco C, Petricoin EF, Mammano E, et al. Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer. Ann Surg Oncol 2007; 14: 2470-6.
8. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002; 48: 1296-304.
9. Engwegen JY, Helgason HH, Cats A, et al. Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J Gastroenterol 2006; 12: 1536-44.
10. Habermann JK, Roblick UJ, Luke BT, et al. Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology 2006; 131: 1020-9.
11. Caspersen MB, Sorensen NM, Schrohl AS, Iversen P, Nielsen HJ, Brunner N. Investigation of tissue inhibitor of metalloproteinases 1 in plasma from colorectal cancer patients and blood donors by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Int J Biol Markers 2007; 22: 89-94.
12. Lim JY, Cho JY, Paik YH, Chang YS, Kim HG. Diagnostic application of serum proteomic patterns in gastric cancer patients by ProteinChip surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Int J Biol Markers 2007; 22: 281-6.
13. Engwegen JY, Mehra N, Haanen JB, et al. Validation of SELDITOF MS serum protein profiles for renal cell carcinoma in new populations. Lab Invest 2007; 87: 161-72.
14. Tolson J, Bogumil R, Brunst E, et al. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 2004; 84: 845-56.
15. Holcakova J, Hernychova L, Bouchal P, et al. Identification of alphaB-crystallin, a biomarker of renal cell carcinoma by SELDI-TOF MS. Int J Biol Markers 2008; 23: 48-53.
16. Becker S, Cazares LH, Watson P, et al. Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. Ann Surg Oncol 2004; 11: 907-14.
17. Hu Y, Zhang S, Yu J, Liu J, Zheng S. SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer. Breast 2005; 14: 250-5.
18. Li J, Orlandi R, White CN, et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem 2005; 51: 2229-35.
19. Banks RE. Preanalytical influences in clinical proteomic studies: raising awareness of fundamental issues in sample banking. Clin Chem 2008; 54: 6-7.
20. Karsan A, Eigl BJ, Flibotte S, et al. Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin Chem 2005; 51: 1525-8.
21. Hu J, Coombes KR, Morris JS, Baggerly KA. The importance of experimental design in proteomic mass spectrometry experiments: some cautionary tales. Brief Funct Genomic Proteomic 2005; 3: 322-31.
22. Engwegen JY, Alberts M, Knol JC, et al. Influence of variations in sample handling on SELDI-TOF MS serum protein profiles for colorectal cancer. Proteomics Clin Appl 2008; 2: 936-45.
23. Hsieh SY, Chen RK, Pan YH, Lee HL. Systematical evaluation of the effects of sample collection procedures on low-molecular-weight serum/ plasma proteome profiling. Proteomics 2006; 6: 3189-98.
24. Rai AJ, Gelfand CA, Haywood BC, et al. HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 2005; 5: 3262-77.
25. Jimenez CR, El Filali Z, Knol JC, et al. Automated serum peptide profiling using novel magnetic C18 beads off-line coupled to MALDI-TOF-MS. Proteomics Clin Appl 2007; 1: 598-604.
26. Kasthuri RS, Verneris MR, Ibrahim HN, Jilma B, Nelsestuen GL. Studying multiple protein profiles over time to assess biomarker validity. Expert Rev Proteomics 2006; 3: 455-64.
27. Mathelin C, Cromer A, Wendling C, Tomasetto C, Rio MC. Serum biomarkers for detection of breast cancers: a prospective study. Breast Cancer Res Treat 2006; 96: 83-90.
28. Song J, Patel M, Rosenzweig CN, et al. Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay. Clin Chem 2006; 52: 1045-53.
29. van Winden AWJ, Gast MCW, Beijnen JH, et al. Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study. BMC Medical Genomics 2008; 2: 4.
30. Fung ET, Yip TT, Lomas L, et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer 2005; 115: 783-9.
31. Timms JF, Arslan-Low E, Gentry-Maharaj A, et al. Preanalytic influence of sample handling on SELDI-TOF serum protein profiles. Clin Chem 2007; 53: 645-56.
32. Villanueva J, Philip J, Chaparro CA, et al. Correcting common errors in identifying cancer-specific serum peptide signatures. J Proteome Res 2005; 4: 1060-72.
33. Arpino G, Laucirica R, Elledge RM. Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med 2005; 143: 446-57.
34. Santen RJ, Mansel R. Benign breast disorders. N Engl J Med 2005; 353: 275-85.
35. Reis-Filho JS, Lakhani SR. The diagnosis and management of pre-invasive breast disease: genetic alterations in preinvasive lesions. Breast Cancer Res 2003; 5: 313-9.
36. Mommers EC, van Diest PJ, Leonhart AM, Meijer CJ, Baak JP. Balance of cell proliferation and apoptosis in breast carcinogenesis. Breast Cancer Res Treat 1999; 58: 163-9.
37. Villanueva J, Shaffer DR, Philip J, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006; 116: 271-84.
38. Garbett EA, Reed MW, Stephenson TJ, Brown NJ. Proteolysis in human breast cancer. Mol Pathol 2000; 53: 99-106.
39. Blasi F. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb Haemost 1999; 82: 298-304.
40. Bank U, Kruger S, Langner J, Roessner A. Review: peptidases and peptidase inhibitors in the pathogenesis of diseases. Disturbances in the ubiquitin-mediated proteolytic system. Protease-antiprotease imbalance in inflammatory reactions. Role of cathepsins in tumour progression. Adv Exp Med Biol 2000; 477: 349-78.
41. Villanueva J, Martorella AJ, Lawlor K, et al. Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol Cell Proteomics 2006; 5: 1840-52.
42. Martinez JM, Prieto I, Ramirez MJ, Cueva C, Alba F, Ramirez M. Aminopeptidase activities in breast cancer tissue. Clin Chem 1999; 45: 1797-802.
43. Ho CH, Yuan CC, Liu SM. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer. Gynecol Oncol 1999; 75: 397-400.
44. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004; 3: 367-78.
45. Diamandis EP. Serum proteomic profiling by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry for cancer diagnosis: next steps. Cancer Res 2006; 66: 5540-1.
46. Bertucci F, Birnbaum D, Goncalves A. Proteomics of breast cancer: principles and potential clinical applications. Mol Cell Proteomics 2006; 5: 1772-86.
47. Hoffman SA, Joo WA, Echan LA, Speicher DW. Higher dimensional (Hi-D) separation strategies dramatically improve the potential for cancer biomarker detection in serum and plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 849: 43-52.
48. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002; 1: 845-67.